Kangweishiji (688426.SH) announced on October 29th that in order to enhance the current molecular testing business level and explore new performance growth opportunities, on October 28, 2024, the company signed an Equity Transfer Agreement with Shanghai Tianhao Biotechnology Co., Ltd. (referred to as Tianhao Biotechnology) with its own funds to acquire 51% equity of Tianhao's wholly-owned subsidiary Shanghai Haotai Biotechnology Co., Ltd. (referred to as Haowaitai) for RMB 12.75 million.

Leveraging Tianhao Biotechnology's more than 10 years of experience in gene sequencing, Haowaitai has taken over all of Tianhao Biotechnology's patents in technology services, as well as various SNP genotyping and gene copy number detection technologies, microbial 16S amplicon absolute quantification, and metagenomic absolute quantification technologies. In the future, it will be committed to providing high-quality gene sequencing services, genetic data analysis, and technical support for research institutions, hospitals, medical colleges, biopharmaceutical companies, and others in the field of genetics, both domestically and internationally.